Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001140361-25-032710
Filing Date
2025-08-26
Accepted
2025-08-26 16:03:35
Documents
2
Period of Report
2025-08-18

Document Format Files

Seq Description Document Type Size
1 FORM 3 form3.html 3  
1 FORM 3 form3.xml 3 1409
2 EXHIBIT 24 ef20054599_ex24.htm EX-24 8831
  Complete submission text file 0001140361-25-032710.txt   11875
Mailing Address 12770 HIGH BLUFF DRIVE SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE SUITE 150 SAN DIEGO CA 92130 (858) 567-7770
GYRE THERAPEUTICS, INC. (Issuer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 12730 HIGH BLUFF DRIVE SUITE 150 SAN DIEGO CA 92130
Business Address
Weng Dan (Reporting) CIK: 0002083482 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-51173 | Film No.: 251257554